99 228

Cited 0 times in

Actual compliance to adjuvant chemotherapy in gastric cancer

DC Field Value Language
dc.contributor.authorKim, DW-
dc.contributor.authorKwon, OK-
dc.contributor.authorYoo, MW-
dc.contributor.authorRyu, SW-
dc.contributor.authorOh, SJ-
dc.contributor.authorHur, H-
dc.contributor.authorHwang, SH-
dc.contributor.authorLee, J-
dc.contributor.authorJin, SH-
dc.contributor.authorLee, SE-
dc.contributor.authorKim, JH-
dc.contributor.authorKim, JJ-
dc.contributor.authorJeong, IH-
dc.contributor.authorJee, YS-
dc.date.accessioned2020-10-21T07:21:24Z-
dc.date.available2020-10-21T07:21:24Z-
dc.date.issued2019-
dc.identifier.issn2288-6575-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/18915-
dc.description.abstractPURPOSE: This study aims to investigate the actual compliance with chemotherapy and analyze several factors affecting the compliance in patients with gastric cancer.
METHODS: From February 2012 to December 2014, we collected data of patients with gastric cancer who received adjuvant chemotherapy (TS-1 monotherapy or XELOX: capecitabine/oxaliplatin) in Korea.
RESULTS: We collected data of 1,089 patients from 31 institutions. The completion rate and dose reduction rate by age (>/=60 years vs. <60 years) were 57.5% vs. 76.8% (P < 0.001) and 17.9% vs. 21.3% (P = 0.354): by body mass index (BMI) (>/=23 kg/m(2) vs. <23 kg/m(2)) were 70.2% vs. 63.2% (P = 0.019) and 19.2% vs. 19.9% (P = 0.987), respectively. The compliance by American Society of Anesthesiologists physical status (ASA PS) classification was as follows: completion rate was 74.4%, 62.8%, and 60% (P = 0.001) and the dose reduction rate was 18.4%, 20.7%, and 17.8% (P = 0.946) in ASA PS classification I, II, and III, respectively. The completion rate of TS-1 and XELOX was 65.9% vs. 70.3% (P = 0.206) and the dose reduction rate was 15.7% vs. 33.6% (P < 0.001). Furthermore, the completion rate of chemotherapy by surgical oncologists and medical oncologists was 69.5% vs. 63.2% (P = 0.028) and the dose reduction rate was 17.4% vs. 22.3% (P = 0.035), respectively.
CONCLUSION: The compliance was lower in patients who were older than 60 years, had BMI <23 kg/m(2), and had higher ASA PS classification. Furthermore, the patients showed higher compliance when they received chemotherapy from surgical oncologists rather than from medical oncologists.
-
dc.language.isoen-
dc.titleActual compliance to adjuvant chemotherapy in gastric cancer-
dc.typeArticle-
dc.identifier.pmid30941322-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444044/-
dc.subject.keywordAdjuvant chemotherapy-
dc.subject.keywordAdvanced gastric cancer-
dc.subject.keywordCompliance-
dc.contributor.affiliatedAuthor허, 훈-
dc.type.localJournal Papers-
dc.identifier.doi10.4174/astr.2019.96.4.185-
dc.citation.titleAnnals of surgical treatment and research-
dc.citation.volume96-
dc.citation.number4-
dc.citation.date2019-
dc.citation.startPage185-
dc.citation.endPage190-
dc.identifier.bibliographicCitationAnnals of surgical treatment and research, 96(4). : 185-190, 2019-
dc.identifier.eissn2288-6796-
dc.relation.journalidJ022886575-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Files in This Item:
30941322.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse